Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1063

2.

Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate.

Brouillette C, Bossé Y, Pérusse L, Gaudet D, Vohl MC.

J Hum Genet. 2004;49(8):424-32. Epub 2004 Jul 13.

PMID:
15249972
3.

Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.

Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, Ayyobi A, Pimstone S, Frohlich J, Ansquer JC, Steiner G; DAIS investigators..

Pharmacogenetics. 2004 Dec;14(12):823-9.

PMID:
15608561
4.

Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women.

Kastelein JJ, Ordovas JM, Wittekoek ME, Pimstone SN, Wilson WF, Gagné SE, Larson MG, Schaefer EJ, Boer JM, Gerdes C, Hayden MR.

Clin Genet. 1999 Oct;56(4):297-305.

PMID:
10636448
7.

Linkage and association studies of the lipoprotein lipase gene with postheparin plasma lipase activities, body fat, and plasma lipid and lipoprotein concentrations: the HERITAGE Family Study.

Garenc C, Pérusse L, Gagnon J, Chagnon YC, Bergeron J, Després JP, Province MA, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C.

Metabolism. 2000 Apr;49(4):432-9.

PMID:
10778864
8.
9.

Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia.

de Bruin TW, Mailly F, van Barlingen HH, Fisher R, Castro Cabezas M, Talmud P, Dallinga-Thie GM, Humphries SE.

Eur J Clin Invest. 1996 Aug;26(8):631-9.

PMID:
8872057
10.

Effect of the APOC3 Sst I SNP on fasting triglyceride levels in men heterozygous for the LPL P207L deficiency.

Garenc C, Couillard C, Laflamme N, Cadelis F, Gagné C, Couture P, Julien P, Bergeron J.

Eur J Hum Genet. 2005 Oct;13(10):1159-65.

11.

The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.

Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.

J Cardiovasc Pharmacol Ther. 2006 Sep;11(3):211-21.

PMID:
17056835
12.

Characterization of LDL particle size among carriers of a defective or a null mutation in the lipoprotein lipase gene: the Québec LIPD Study.

Ruel IL, Gaudet D, Perron P, Bergeron J, Julien P, Lamarche B.

Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1181-6.

14.

Genetic epistasis in the VLDL catabolic pathway is associated with deleterious variations on triglyceridemia in obese subjects.

Brisson D, St-Pierre J, Santuré M, Hudson TJ, Després JP, Vohl MC, Gaudet D.

Int J Obes (Lond). 2007 Aug;31(8):1325-33. Epub 2007 Mar 6.

PMID:
17342071
15.

Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation.

Andersson Y, Majd Z, Lefebvre AM, Martin G, Sechkin AV, Kosykh V, Fruchart JC, Najib J, Staels B.

Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):115-21.

17.

Relationship between plasma HDL subclasses distribution and lipoprotein lipase gene HindIII polymorphism in hyperlipidemia.

Long S, Tian Y, Zhang R, Yang L, Xu Y, Jia L, Fu M.

Clin Chim Acta. 2006 Apr;366(1-2):316-21. Epub 2005 Dec 20.

PMID:
16364275
18.

Apolipoprotein E genotype and changes in serum lipids and maximal oxygen uptake with exercise training.

Thompson PD, Tsongalis GJ, Seip RL, Bilbie C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Bausserman L, Moyna N.

Metabolism. 2004 Feb;53(2):193-202.

PMID:
14767871
19.

Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study.

Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM.

Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):805-10.

20.

Apolipoprotein E and lipoprotein lipase gene polymorphisms interaction on the atherogenic combined expression of hypertriglyceridemia and hyperapobetalipoproteinemia phenotypes.

Perron P, Brisson D, Santuré M, Blackburn P, Bergeron J, Vohl MC, Després JP, Gaudet D.

J Endocrinol Invest. 2007 Jul-Aug;30(7):551-7.

PMID:
17848837

Supplemental Content

Support Center